SAPROPTERIN DIHYDROCHLORIDE Drug Patent Profile

When do Sapropterin Dihydrochloride patents expire, and when can generic versions of Sapropterin Dihydrochloride launch?

Sapropterin Dihydrochloride is a drug marketed by Annora Pharma, Dr Reddys, Micro Labs, Ph Health, Tp Anda Holdings, Aurobindo Pharma, and Zenara. and is included in twelve NDAs.

The generic ingredient in SAPROPTERIN DIHYDROCHLORIDE is sapropterin dihydrochloride. There are three drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sapropterin Dihydrochloride

A generic version of SAPROPTERIN DIHYDROCHLORIDE was approved as sapropterin dihydrochloride by PH HEALTH on May 10^th, 2019.

Summary for SAPROPTERIN DIHYDROCHLORIDE

US Patents:	0
Applicants:	7
NDAs:	12
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	41
Patent Applications:	355
Drug Prices:	Drug price information for SAPROPTERIN DIHYDROCHLORIDE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAPROPTERIN DIHYDROCHLORIDE
What excipients (inactive ingredients) are in SAPROPTERIN DIHYDROCHLORIDE?	SAPROPTERIN DIHYDROCHLORIDE excipients list
DailyMed Link:	SAPROPTERIN DIHYDROCHLORIDE at DailyMed

See drug prices for SAPROPTERIN DIHYDROCHLORIDE

Recent Clinical Trials for SAPROPTERIN DIHYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
APR Applied Pharma Research s.a.	PHASE1
Innovent Biologics (Suzhou) Co. Ltd.	PHASE2
Sun Yat-sen University	PHASE2

See all SAPROPTERIN DIHYDROCHLORIDE clinical trials

Pharmacology for SAPROPTERIN DIHYDROCHLORIDE

Drug Class	Phenylalanine Hydroxylase Activator
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors Phenylalanine Hydroxylase Activators

Anatomical Therapeutic Chemical (ATC) Classes for SAPROPTERIN DIHYDROCHLORIDE

A16AX	Various alimentary tract and metabolism products
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for SAPROPTERIN DIHYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KUVAN	Powder for Oral Solution	sapropterin dihydrochloride	500 mg per packet	205065	1	2017-02-23
KUVAN	Powder for Oral Solution	sapropterin dihydrochloride	100 mg per packet	205065	1	2015-11-09
KUVAN	Tablets	sapropterin dihydrochloride	100 mg	022181	1	2014-06-05

US Patents and Regulatory Information for SAPROPTERIN DIHYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Annora Pharma	SAPROPTERIN DIHYDROCHLORIDE	sapropterin dihydrochloride	POWDER;ORAL	215420-001	Aug 18, 2022	AB	RX	No	No
Ph Health	SAPROPTERIN DIHYDROCHLORIDE	sapropterin dihydrochloride	POWDER;ORAL	207207-001	Aug 20, 2019	AB	RX	No	No
Dr Reddys	SAPROPTERIN DIHYDROCHLORIDE	sapropterin dihydrochloride	POWDER;ORAL	215798-001	May 13, 2022	AB	RX	No	No

Market Dynamics and Financial Trajectory for Sapropterin Dihydrochloride

Last updated: March 5, 2026

What Is Sapropterin Dihydrochloride?

Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin (BH4), a cofactor required for phenylalanine hydroxylase activity. It is approved for treating phenylketonuria (PKU), a rare metabolic disorder characterized by elevated phenylalanine levels. The drug enhances enzyme function, reducing phenylalanine accumulation.

Market Overview

Indications and Approved Uses

• Primary: PKU in patients aged 4 and older
• Off-label: Investigated for conditions like hyperphenylalaninemia and other rare metabolic disorders

Key Manufacturers

• BioMarin Pharmaceutical
• Merck KGaA (as of recent patent expiries and market shifts)
• Other regional generic producers

Regulatory Status

• Approved in the U.S. by the FDA in 2007
• EMA approval in 2008
• Market exclusivity: Patent protection extended until 2024 in some regions; generics launched thereafter

Market Drivers and Challenges

Drivers

• Increased diagnosis of PKU: Neonatal screening programs in developed countries. Estimated PKU prevalence varies from 1 in 10,000 to 1 in 15,000 live births.
• Limited treatment options: Few approved therapies for PKU. Sapropterin boosts quality of life and dietary compliance.
• Expansion of indications: Investigations into other metabolic disorders suggest potential growth.

Challenges

• High cost: Average annual treatment cost exceeding $100,000 in the U.S.
• Limited efficacy in some patients: Response rate about 30–50%; only responder subsets benefit.
• Generic entry: Post-patent expiration, price competition may reduce revenue.

Market Size and Revenue Estimates

• Global PKU treatment market estimated at $600 million in 2022.
• Sapropterin commands the majority share in approved therapies.
• Revenue Trends:

Year	Global Revenue (USD millions)	Market Share of Sapropterin
2018	500	70%
2019	550	72%
2020	600	74%
2021	650	75%
2022	660	76%

• The market is projected to grow modestly at approximately 3-4% CAGR through 2027, driven by expanding neonatal screening and potential new indications.

Financial Trajectory

Revenue Trends

• BioMarin's flagship product, Kuvan (brand for sapropterin), generates around $400–450 million annually.
• Growth rates have plateaued since 2020 due to patent expiry pressures and rising generic competition.
• Patent expiry date in key markets: 2024; generic entry expected thereafter.

Cost Structure and Margins

• R&D expenses allocated toward expanding indications and optimizing formulations.
• Gross margins approximately 75%, with net margins around 50% pre-generic entry.
• Post-2024, margins likely decline due to price erosion.

Market Entry of Generics

• As of 2025, multiple generic manufacturers launched biosimilar versions.
• Price reductions of up to 50% anticipated, leading to significant revenue declines for originators.
• Biosimilar market penetration could take 1-2 years post-launch in mature regions.

Regulatory and Policy Impact

• Policies favoring cost-effective treatments may pressure prices.
• Potential for price negotiations and reimbursement restrictions in some markets.
• Emerging regulatory pathways for biosimilars may ease market entry.

Future Outlook

• Pipeline development: Research into alternative cofactor therapies and gene editing.
• Market expansion: Limited potential beyond PKU and related rare diseases.
• Pricing pressure: Intensifies after patent expiration, demanding strategic cost management.

Key Takeaways

• The market for sapropterin dihydrochloride is characterized by steady revenue dominated by BioMarin.
• Patent expiration in 2024 is a major inflection point, with generic competition poised to erode profitability.
• Growth drivers are primarily from increased PKU diagnoses and expanded neonatal screening.
• The limited responder population constrains sales growth.
• Cost containment and pipeline innovation are critical for sustained profitability.

FAQs

1. What is the primary market for sapropterin dihydrochloride?
   PKU treatment in patients aged 4 and above, primarily in the U.S. and Europe.

2. When will generic versions of sapropterin become available?
   After patent expiration, expected in 2024–2025, with biosimilars entering markets shortly thereafter.

3. What factors influence demand for sapropterin?
   Awareness and implementation of neonatal screening, responder rates, and regulatory approvals.

4. How does the drug’s high cost affect market dynamics?
   It limits access in some regions and puts pressure on manufacturers facing reimbursement negotiations.

5. Are there opportunities for growth beyond the current indications?
   Potential exists in rare metabolic disorders under investigation, but current revenues mainly depend on PKU.

References

[1] BioMarin Pharmaceutical. (2022). Annual Report.
[2] U.S. Food and Drug Administration. (2007). Approval of Kuvan.
[3] European Medicines Agency. (2008). Summary of Product Characteristics for Sapropterin.
[4] MarketsandMarkets. (2023). Rare Disease Treatment Market Forecast.
[5] IQVIA. (2022). Global Pharmaceutical Market Data.